C E Lloyd1, N Sartorius2, L C Cimino3, A Alvarez4, M Guinzbourg de Braude5, G Rabbani6, H Uddin Ahmed7, M Papelbaum8, S Regina de Freitas8, L Ji9, X Yu10, W Gaebel11, K Müssig12,13, S K Chaturvedi14, S S Srikanta15,16, L Burti17, V Bulgari18, A Musau19, D Ndetei20, G Heinze21, F Romo Nava21, R Taj22, A Khan22, A Kokoszka23, A Papasz-Siemieniuk23, E G Starostina24, A E Bobrov25, D Lecic-Tosevski26, N M Lalic27, P Udomratn28, S Tangwongchai29, S Bahendeka30, D Basangwa30, B Mankovsky31. 1. Faculty of Health & Social Care, The Open University, UK. 2. Association for the Improvement of Mental Health Programmes (AMH), Geneva, Switzerland. 3. Indiana University, USA. 4. Endocrinology, Metabolism and Nuclear Medicine, Hospital Italiano de Buenos Aires, Argentina. 5. Psychiatry Service, Hospital Italiano de Buenos Aires, Argentina. 6. Department of Psychiatry, Popular Medical College, Dhaka, Bangladesh. 7. Child Adolescent & Family Psychiatry, National Institute of Mental Health (NIMH), Dhaka, Bangladesh. 8. Obesity and Eating Disorders Group - State Institute of Diabetes and Endocrinology of Rio de Janeiro, Brazil. 9. Department of Endocrinology and Metabolism, People's Hospital, Peking University, Beijing, China. 10. Institute of Mental Health, Peking University, Beijing, China. 11. Department of Psychiatry and Psychotherapy, Medical Facility, Heinrich Heine University, Düsseldorf, Germany. 12. Institute for Clinical Diabetology, German Diabetes Centre, Leibniz Centre for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany. 13. Department of Endocrinology and Diabetology, University Hospital Düsseldorf, Düsseldorf, Germany. 14. National Institute of Mental Health & Neurosciences, Bangalore, India. 15. Samatvam Endocrinology Diabetes Centre, Bangalore, India. 16. Jnana Sanjeevini Medical Centre, Bangalore, India. 17. Department of Public Health and Community Medicine, University of Verona, Brescia, Italy. 18. Unit of Psychiatry Epidemiology and Evaluation Unit, St John of God Clinical Research Centre, Brescia, Italy. 19. Africa Mental Health Foundation, Kenya. 20. University of Nairobi, Africa Mental Health Foundation, Kenya. 21. Department of Psychiatry and Mental Health, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico. 22. Pakistan Institute of Medical Sciences, Islamabad, Pakistan. 23. Department of Psychiatry, Medical University, Warszawa, Poland. 24. Department of Endocrinology, Moscow Regional Clinical and Research Institute, Moscow, Russia. 25. Moscow Research Institute of Psychiatry, Moscow, Russia. 26. Serbian Academy of Sciences and Arts, Institute of Mental Health, School of Medicine, University of Belgrade, Belgrade, Serbia. 27. Clinic for Endocrinology, Serbian Academy of Sciences and Arts, School of Medicine, University of Belgrade, Belgrade, Serbia. 28. Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. 29. Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 30. The Mother Kevin Post Graduate Medical School, Uganda Martyrs University, Kampala, Uganda. 31. Department of Diabetology, National Medical Academy for Postgraduate Education, Kiev, Ukraine.
Abstract
AIM: People with diabetes are at an increased risk of developing depression and other psychological disorders. However, little is known about the prevalence, correlates or care pathways in countries other than the UK and the USA. A new study, the International Prevalence and Treatment of Diabetes and Depression Study (INTERPRET-DD) aims to address this dearth of knowledge and identify optimal pathways to care across the globe. METHOD: INTERPRET-DD is a 2-year longitudinal study, taking place in 16 countries' diabetes outpatients' facilities, investigating the recognition and management of depressive disorders in people with Type 2 diabetes. Clinical interviews are used to diagnose depression, with clinical and other data obtained from medical records and through patient interviews. Pathways to care and the impact of treatment for previously unrecognized (undocumented) depression on clinical outcomes and emotional well-being are being investigated. RESULTS: Initial evidence indicates that a range of pathways to care exist, with few of them based on available recommendations for treatment. Pilot data indicates that the instruments we are using to measure both the symptoms and clinical diagnosis of depression are acceptable in our study population and easy to use. CONCLUSIONS: Our study will increase the understanding of the impact of comorbid diabetes and depression and identify the most appropriate (country-specific) pathways via which patients receive their care. It addresses an important public health problem and leads to recommendations for best practice relevant to the different participating centres with regard to the identification and treatment of people with comorbid diabetes and depression.
AIM: People with diabetes are at an increased risk of developing depression and other psychological disorders. However, little is known about the prevalence, correlates or care pathways in countries other than the UK and the USA. A new study, the International Prevalence and Treatment of Diabetes and Depression Study (INTERPRET-DD) aims to address this dearth of knowledge and identify optimal pathways to care across the globe. METHOD: INTERPRET-DD is a 2-year longitudinal study, taking place in 16 countries' diabetes outpatients' facilities, investigating the recognition and management of depressive disorders in people with Type 2 diabetes. Clinical interviews are used to diagnose depression, with clinical and other data obtained from medical records and through patient interviews. Pathways to care and the impact of treatment for previously unrecognized (undocumented) depression on clinical outcomes and emotional well-being are being investigated. RESULTS: Initial evidence indicates that a range of pathways to care exist, with few of them based on available recommendations for treatment. Pilot data indicates that the instruments we are using to measure both the symptoms and clinical diagnosis of depression are acceptable in our study population and easy to use. CONCLUSIONS: Our study will increase the understanding of the impact of comorbid diabetes and depression and identify the most appropriate (country-specific) pathways via which patients receive their care. It addresses an important public health problem and leads to recommendations for best practice relevant to the different participating centres with regard to the identification and treatment of people with comorbid diabetes and depression.
Authors: Ewelina Cichoń; Andrzej Kiejna; Tomasz M Gondek; Marcin Obrębski; Edyta Sutkowska; Cathy E Lloyd; Norman Sartorius; Andrzej Kokoszka Journal: Diabetes Metab Syndr Obes Date: 2021-11-02 Impact factor: 3.168
Authors: Ewelina Cichoń; Andrzej Kiejna; Andrzej Kokoszka; Tomasz M Gondek; Rafał Radzio; Adam Jastrzębski; Beata E Andrzejewska; Fahad D Alosaimi; Cathy E Lloyd; Norman Sartorius Journal: PLoS One Date: 2020-10-23 Impact factor: 3.240